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INTRODUCTION
For centuries, skin diseases have been
described according to their macro-
morphological appearance and classified
according the morphological description.
The system of grouping morphological fea-
tures in skin diseases followed the same
principles as defined by Carolus Linnaeus
(1707–1778) in the taxonomy of plants and
animals.
The major development of the mor-
phological description of skin diseases
was following extensive application of
dermatopathology on skin biopsies. By
integrating macro- and micromorphol-
ogy, a new system for description of skin
diseases had been created the primary
efflorescences. The primary efflorescences
constitute a set of macromorphological
characteristics, which are indicative for
the most important general pathological
features (1). This system has served and
still serves the classification of skin dis-
eases. The primary efflorescences are the
essentials in descriptions, diagnosis, and
treatment of dermatoses. Dermatoses are
classified from the point of view of the
fundamental pathologic process involved.
In other words, the classification is made
according to the essential lesions.
During the last four decades important
new insights in the genetics, pathophysiol-
ogy, and cell biology have provided cru-
cial information about the etiology and
pathogenesis of skin diseases and have
developed dermatology from a morphol-
ogy driven discipline into an etiology
based discipline. These observations have
impacted the system of classification of
skin diseases and the possibility for targeted
treatments. The development of etiology
based disease classification and targeted
treatments have brought dermatology in
better alignment with other medical disci-
plines such as internal medicine, rheuma-
tology, and gastroenterology. In particu-
lar, the multidisciplinary approach in sys-
temic diseases provides etiological concepts
beyond the boundaries of the individual
disciplines.
Skin diseases are easily accessible for
inspection and investigation. That is why
skin diseases are at the frontiers for
advancement of insights in the etiology
and pathogenesis of diseases and for under-
standing the mode of action of treatments.
A major question is whether classical
dermatology in general practice can serve
to the patients in the light of new devel-
opments? On one hand, there is a major
challenge for teaching and continuing edu-
cation. On the other hand, dermatology
networks around centers of excellence are
and will be of major importance in the
future.
DIAGNOSIS OF SKIN DISEASES
GENODERMATOSES
Genetic technology over the past decade
has generated new knowledge in the asso-
ciation of allelic variations in several genes
with specific skin diseases. As of today, the
genetic bases of the majority of the more
common genodermatoses are known. Our
insight into the biology of skin diseases has
increased accordingly.
Genetic counseling has been greatly
aided by gene identification, DNA-based
prenatal diagnosis in several conditions,
and DNA-based preimplantation diagnosis
has been used. A summary of genoder-
matoses associated with allelic variations
in known genes is provided in the classic
review by Irvine and McLean (2).
Irvine and McLean defined important
gaps in our knowledge and directions for
future research:
- genotype–phenotype correlation: clini-
cal heterogeneity implies that different
phenotypes may arise from one muta-
tion; genetic heterogeneity implies that
the same phenotype may arise from
different mutations
- variable penetrance may cause different
phenotypes
- revertant mosaicism is a well-known
phenomenon, which contribute to the
complexity of phenotype – genotype
correlations.
Further investigations of the underly-
ing mechanisms will give better clues to
the clinical understanding of the genetic
abnormalities. For the nosology of skin dis-
eases, classical morphological description
will permit adequate diagnosis in many
patients. However, a new approach is pos-
sible, focused on the genetic observations
in stead of clinical descriptions (3–5). For
clinical practice, new technology may pro-
vide new opportunities and also ethical
challenges. In particular, with respect to
prenatal diagnosis and postnatal diagnosis,
the knowledge about a genotype may pose
questions with respect to termination of
pregnancies and questions to interventions
intended.
INFLAMMATORY DERMATOSES
Inflammatory dermatoses comprise a spec-
trum of different diseases. Based on the
clinical description, different disease enti-
ties have been defined, which may be
restricted to the skin or may be a systemic
disease. Inflammatory diseases share or
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may have distinct pathogenetic processes,
which may harbor a target for anti-
inflammatory treatments.
For example, a disease such as psori-
asis remain in the majority of patients
restricted to a few erythematosquamous
plaques, without any sign of systemic
inflammation and can be treated with a
topical treatment (vitamin D analog and/or
corticosteroid). About 1/3 rd of patients
with psoriasis has more widespread disease,
with co-morbidities such as arthritis and
metabolic syndrome. So far, the course of
the disease is chronic and unpredictable.
The etiology of psoriasis is unknown.
Several genes have shown to be involved
(6). These genes comprise various patho-
genetic processes such as IL-23 and IL
17 signaling, Interferon gamma signaling,
NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells) signaling,epi-
dermal proliferation, and keratinization.
The question arises to what extent psori-
asis harbors different genotypes, which are
reflected in different phenotypes. Indeed,
it has been shown that the chronic plaque
psoriasis and pustular psoriasis are differ-
ent diseases, with respect to genotype and
phenotype (7). Further studies are needed
to understand better, the differences in clin-
ical aspects of psoriasis in the light of
different genes involved in the individual
patients.
Phototherapy, methotrexate, cyclo-
sporin, acitretin, and fumarates are the
most established classical treatments for
psoriasis. In case of insufficient control
treatment with anti-TNF biologics (etan-
ercept, adalimumab, or infliximab) or with
the anti Il12–23 (ustekinumab). It remains
an art to select the appropriate treatment
in an individual patient based on relevant
co-morbidities and the requirement of
therapeutic strength.
Every patient has his/her own psoriasis
and that is true, in particular, with respect
to treatment. Current interest is on devel-
opment of co-diagnostics to predict the
course of the disease and responsiveness
to the various treatments. Genetic mark-
ers, immune markers, and pharmacological
markers are helpful.
ONCOLOGY
NON-MELANOMA SKIN CANCER
Non-melanoma skin cancer (NMSC) is
the most frequent malignancies of the
skin. During the last 3 decades an impor-
tant increases of NMSC has been noticed,
resulting from more extensive exposition of
the skin to UV radiation. The diagnosis and
subsequent treatment of premalignancies
and malignancies belonging to NMSC are
a major task for dermatologists and general
practitioners. An important future possi-
bility to facilitate rapid diagnosis is in vivo
confocal microscopy (8). However, it has to
be realized that the restricted in vivo pen-
etration of the laser light is an important
limitation of this method.
MELANOMA
Mutations in BRAF-oncogene are respon-
sible for continuous growth in 60% of
melanoma’s (9). Other mutations are in
KIT – gene in acral, mucosal, and lentigo
melanoma (10). Various kinase inhibitors
inhibit kinases associated with continuous
growth of melanoma via individual muta-
tions. Further studies on relevant muta-
tions and the molecular control of growth
induced by these oncogenes may lead to a
target therapy of advanced melanoma.
TARGETED TREATMENTS
GENODERMATOSES
Therapeutic strategies according to the
underlying genetic mechanisms have been
developed. The easy access to the skin com-
pared with solid internal organs, provides
unique opportunities for cutaneous gene
therapy; however, many technical issues
have to be addressed to enable gene replace-
ment or modification of gene expression in
genetic diseases.
With ex vivo cutaneous gene therapy, a
gene therapy vector is incorporated in cul-
tured keratinocytes derived from a patient
s biopsy and then grafted back onto the
patient’s skin using well-established tech-
nology developed for the treatment of
burns and, more recently, for stable vitiligo
(11). Mutant gene expression has been suc-
cessfully rescued in cultured keratinocytes
from a variety of recessive genodermatoses,
including Recessive Dystrophic Epider-
molysis Bullosa – Herlitz (RDEB-HS) (12)
junctional epidermolysis bullosa, type Her-
litz (JEB-H) (13), and others. The sys-
tem has been used to treat successfully
cells from patients with JEB-H (14) and
X-linked ichthyosis (15).
In vivo gene therapy provides direct
transfer of a therapeutic gene construct
into the skin of the patient. One difficulty
here is getting DNA past the highly evolved
barrier function of the skin.
mRNA inactivation have been devel-
oped, based on short inhibitory RNA
(siRNA) technology (16). Another RNA-
based approach is that of RNA trans-
splicing, aimed at correcting mutations in
recessive or dominant conditions. This has
recently been used to correct mutations in
collagen XVII in vitro (17).
Gene repair oligonucleotides are small
DNA–RNA hybrid molecules that can tar-
get and correct the mutation within a given
gene.
INFLAMMATORY DERMATOSES
Although many patients are treated with
topicals, phototherapy, and laser treat-
ments the major innovations were not pri-
marily in this area. Development of patho-
genesis based treatments was possible by
the interventions with biologics targeted
at specific sites in the pathogenesis of
inflammatory diseases.
A variety of classical anti-inflammatory
treatments and innovative targeted treat-
ments (biologics and small molecules) are
available. In particular, in the field of pso-
riasis new treatments are currently devel-
oped. These applications may often be of
benefit for other inflammatory diseases.
Reverting to psoriasis, so far no early
biomarkers, indicative for a more active
course with more widespread disease or
systemic involvement are available. So far,
the question whether early active interven-
tion is needed in at least some patients is
not known (18).
During the course of the disease, it
is very difficult to indicate with cer-
tainty, whether a systemic treatment with
a classical antipsoriatic drug (methotrex-
ate, fumarates, cyclosporin, or retinoids) is
indicated in an individual, or whether the
patient has to be treated with a biologic
(either anti-TNF or ustekinumab).
So far, some evidence is available that
plasma through levels of biologics are
important to avoid under – and over-
dosing (19, 20) Some evidence is avail-
able that TNFAIP3 gene polymorphism
will be associated with better responsive-
ness to anti-TNF (21) and HLA-Cw6 but
not LCE3B/3C deletion nor TNFAIP3 poly-
morphism will be associated with better
responsiveness to ustekinumab (22).
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In psoriasis, new treatments in devel-
opment are the biologics with anti-IL-17
action, anti IL-23, and the small mol-
ecules apremilast (anti-phosphodiesterase
4) and tofacitinib (JANUS kinase inhibitor)
(23–29).
Future research is focused on under-
standing, which treatment has to be given
to which patient and when. Biomarkers
and co-diagnostics to help guiding future
treatment in the individual patients are of
crucial value to provide optimal care.
With the development of small mol-
ecules, new innovative topical treat-
ments will become reality in the near
future. Pathogenesis based treatments will
than innovate the management of fre-
quently occurring more mild expressions
of inflammatory skin diseases.
ONCOLOGY
NON-MELANOMA SKIN CANCER
In addition to the traditional treatments
such as surgery, cryotherapy and radiother-
apy, and photo dynamic therapy, stimula-
tion of cytotoxic immunity by imiquimod
is an important advance (30). In future, fur-
ther immunostimulatory treatments may
provide important opportunities for tar-
geted treatment of NMSC.
MELANOMA
Targeted therapy with inhibitors of the
BRAF and MKE proteins is well-established
for those patients with BRAF-mutant
melanoma (31). However, following a clin-
ical response, resistance develops in the
tumors treated with these agents.
Another new approach is immunother-
apy with antibodies, modulating the inter-
action between dendritic cells and T lym-
phocytes by blocking CTLA-4 and PD-1
(31–33). This results in augmented cell
immunity and in a durable clinical
response in melanoma patients.
FUTURE PROSPECTS
Further studies beyond the boundaries of
clinical classification may help to define
stratification, which is relevant to the
course of a disease and with respect to
responsiveness to individual treatments.
Indeed, personalized medicine will pro-
vide important future opportunities. This
impacts our research, which so far often
was focused on “group analyses,” into
approach to focus on individual geno-
typical and phenotypical identifications.
For the society, individualized personalized
care will be more cost effective as unnec-
essary interventions can be restricted to
focused individualized care.
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